Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 6
2006 13
2007 19
2008 25
2009 29
2010 51
2011 134
2012 228
2013 309
2014 400
2015 294
2016 127
2017 65
2018 26
2019 18
2020 17
2021 28
2022 18
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

1,595 results

Results by year

Filters applied: . Clear all
Page 1
Telaprevir.
[No authors listed] [No authors listed] 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999669 Free Books & Documents. Review.
Telaprevir is no longer marketed in the United States and has not been studied in nursing mothers. ...When it was marketed, the manufacturer recommended that mothers taking telaprevir not breastfeed their infants....
Telaprevir is no longer marketed in the United States and has not been studied in nursing mothers. ...When it was marketed, the manuf …
Telaprevir.
[No authors listed] [No authors listed] Drugs R D. 2010;10(3):179-202. doi: 10.2165/11586020-000000000-00000. Drugs R D. 2010. PMID: 20945948 Free PMC article. Review.
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. ...As the first ever HCV protease inhibito …
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) i …
[Telaprevir resistance].
Poveda E, García F. Poveda E, et al. Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Enferm Infecc Microbiol Clin. 2013. PMID: 24063900 Review. Spanish.
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus (HCV), this potency can be compromised by the rapid emergence of resistance mutations. ...The presence of polymorphisms or mutations associ …
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus …
Telaprevir-related dermatitis.
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Roujeau JC, et al. JAMA Dermatol. 2013 Feb;149(2):152-8. doi: 10.1001/jamadermatol.2013.938. JAMA Dermatol. 2013. PMID: 23560295 Clinical Trial.
Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were suspected, with 2 SJS and 3 DRESS cases considered likely. CONCLUSIONS: Telaprevir-related dermatitis occurs in a majority of telaprevir …
Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were suspected, …
[Pharmacovigilance update].
Diezi L, Renard D, Rothuizen LE, Livio F. Diezi L, et al. Rev Med Suisse. 2014 Jan 15;10(412-413):119-22. Rev Med Suisse. 2014. PMID: 24558915 Review. French.
Retigabine: indication restricted to last-line use and new monitoring requirements after reports of pigment changes in retina and other tissues. Telaprevir and rituximab: severe mucocutaneous reactions. Fingolimod: rare cases of progressive multifocal leucoencephalopathy. …
Retigabine: indication restricted to last-line use and new monitoring requirements after reports of pigment changes in retina and other tiss …
VX-950 (Vertex/Mitsubishi).
Summa V. Summa V. Curr Opin Investig Drugs. 2005 Aug;6(8):831-7. Curr Opin Investig Drugs. 2005. PMID: 16121690 Review.
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase …
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhi …
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Forestier N, et al. Hepatology. 2007 Sep;46(3):640-8. doi: 10.1002/hep.21774. Hepatology. 2007. PMID: 17879366 Clinical Trial.
Telaprevir (VX-950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. ...Day 15 HCV RNA levels were undetectable in 4 patients who received telaprevir and peginterfero …
Telaprevir (VX-950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RN …
Telaprevir user's guide.
Liapakis AM, Jacobson I. Liapakis AM, et al. Liver Int. 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. Liver Int. 2012. PMID: 22212567 Review.
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a regimen of telaprevir combined with pegylated interferon alfa and ribavirin (PR) over PR alone in patients with HCV genotype 1. ...Stopp …
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a reg …
Optimizing treatment in HIV/HCV coinfection.
Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Puoti M, et al. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S355-62. doi: 10.1016/j.dld.2013.09.001. Dig Liver Dis. 2013. PMID: 24091116 Review.
Results of anti-HCV treatment are poor, and less than 50% of treated patients show SVR to peginterferon plus ribavirin combination therapy; in infections from HCV genotype 1 this proportion is less than 40%. Pilot studies have demonstrated that Boceprevir or Telaprevir in …
Results of anti-HCV treatment are poor, and less than 50% of treated patients show SVR to peginterferon plus ribavirin combination therapy; …
Biocatalytic retrosynthesis.
Turner NJ, O'Reilly E. Turner NJ, et al. Nat Chem Biol. 2013 May;9(5):285-8. doi: 10.1038/nchembio.1235. Nat Chem Biol. 2013. PMID: 23594772 No abstract available.
1,595 results